WEST PHARMACEUTICAL SERVICES, INC. FY 2025 10-K, explained in plain English
Key financials — as reported
| Total revenue | $3.1B |
| Gross margin | 35.9% |
| Operating income | $584.9M |
| Net income | $493.7M |
| Diluted EPS | $6.79 |
| Cash & equivalents | $791.3M |
| Total assets | $4.3B |
| Long-term debt | $202.8M |
Key takeaway
West Pharmaceutical Services reported $3.07 billion in revenue and $493.7 million in net income for fiscal 2025.
🔒 4 more takeaways in the full analysis
Beneath the surface
Net cash position is strongly positive: $791.3 million in cash versus only $202.8 million in long-term debt, implying net cash of roughly $588 million rather than a leveraged balance sheet.
🔒 4 more insights a headline reader would miss
This is the free preview. The full analysis explains every line item above and includes 8 more findings — plus insider trades, activist stakes, and 8-K events for WST.
Read the full analysis free Free account · 5 full analyses included · no card required